Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › glatiramer acetate

glatiramer acetate

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of glatiramer acetate

8 trials tracked of glatiramer acetate: 5 in phase 3 or 4.

8Trials tracked
5Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 4 1 Phase 3 4 Phase 2 3
  1. Phase 4 Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness Completed
  2. Phase 3 Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis Completed
  3. Phase 3 A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon) Completed
  4. Phase 3 Safety of New Formulation of Glatiramer Acetate Completed
  5. Phase 3 Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx Completed
  6. Phase 2 Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone) Completed
Show 2 more trials
  1. Phase 2 Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate Completed
  2. Phase 2 Treatment Interruption of Natalizumab Completed

Showing the 8 most-cited and recently-updated of 8 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
MRI outcomes show weak association with disability in primary progressive multiple sclerosis patients
Neurology Phase III
MRI outcomes show weak association with disability in primary progressive multiple sclerosis patients MRI results show weak connection to disability changes in progressive multiple sclerosis
This Phase 3 trial secondary analysis evaluated 943 patients with primary progressive multiple sclerosis treated with glatiramer acetate ove…
MRI scans show weak links to disability changes in progressive multiple sclerosis, challenging their use as reliable trial endpoints for thi…
Apr 16, 2026